Population pharmacokinetics of quinidine.

Population pharmacokinetics of omeprazole in a random Iranian population

Background: Omeprazole is metabolized predominantly by CYP2C19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. These variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. The aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random Iranian population. Met...

Smooth Nonparametric Maximum Likelihood Estimation for Population Pharmacokinetics , with Application to Quinidine 1

Pharmacokinetics of quinine, quinidine and Cinchonine when given as combination.

Pharmacokinetics of quinine, quinidine and cinchonine when given as a combination were evaluated in Thai patients with falciparum malaria during acute infection and convalescence. The combination of quinine, quinidine and cinchonine was randomly given to thirteen patients at 400 mg or 600 mg (consisting of one-third of each component; 7 patients were enrolled in 400 mg regimen and 6 in 600 mg r...

population pharmacokinetics of omeprazole in a random iranian population

background: omeprazole is metabolized predominantly by cyp2c19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. these variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. the aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random iranian population. met...

Population pharmacokinetics of exenatide

AIM The aim of the present analysis was to develop a core population pharmacokinetic model for the pharmacokinetic properties of immediate-release (IR) exenatide, which can be used in subsequent analyses of novel sustained-release formulations. METHODS Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis. All modell...